Abstract
Immunization with irradiated sporozoites can protect against malaria infection and intensive efforts are aimed at reproducing this effect with subunit vaccines. A particular sequence of subunit immunization with pre-erythrocytic antigens of Plasmodium berghei, consisting of single dose priming with plasmid DNA followed by a single boost with a recombinant modified vaccinia virus Ankara (MVA) expressing the same antigen, induced unprecedented complete protection against P. berghei sporozoite challenge in two strains of mice. Protection was associated with very high levels of splenic peptide-specific interferon-γ-secreting CD8+ T cells and was abrogated when the order of immunization was reversed. DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells.
Similar content being viewed by others
Article PDF
References
Nussenzweig, V. & Nussenzweig, R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45, 283–334 (1989).
Hill, A.V.S. et al Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360, 434–439 (1992).
Aidoo, M. et al Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 345, 1003–1007 (1995).
Rodrigues, M.M. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Immunol. 3, 579–585 (1991).
Romero, P. et al Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341, 323–326 (1989).
White, K.L., Snyder, H.L. & Krzych, U. MHC class l-dependent presentation of exoety-throcytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei. J. Immunol. 156, 3374–3381 (1996).
Doolan, D.L. et al Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J. Exp. Med. 183,1739–1746 (1996).
Sedegah, M., Hedstrom, R., Hobart, P. & Hoffman, S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci. USA 91, 9866–9870 (1994).
Doolan, D.L. & Hoffmann, S.L. Multi-gene vaccination against malaria: A multistage, multi-immune response approach. Parasitol. Today 13, 171–178 (1997).
Bennink, J.R. et al. Recombinant vaccinia virus primes and stimulates influenza haemag-glutinin-specific cytotoxic T cells. Nature 311, 578–579 (1984).
Bender, B.S. et al. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70, 6418–6424 (1996).
Thomson, S.A. et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 157, 822–826 (1996).
An, L.L., Pamer, E. & Whitton, J.L. A recombinant minigene vaccine containing a norv americ cytotoxic-T-lymphocyte epitope confers limited protection against Listeria mono-cytogenes infection. Infect. Immun. 64, 1685–1693 (1996).
Satchidanandam, V., Zavala, F. & Moss, B. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Mol. Biochem. Parasitol. 48, 89–99 (1991).
Sedegah, M. et al. Active and passive immunization against Plasmodium yoelii sporozoites. Bull. World Health Organ. 68, 1009–1014 (1990).
Stickl, H., & Hochstein-Mintzel, V. Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (“MVA virus”). Munch. Med/Wochenschr. 113, 1149–1153(1971).
Mayr, A. et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. 167, 375–390 (1978).
Sutter, G. & Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89, 10847–10851 (1992).
Sutter, G. et al. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032–1040 (1994).
Symons, J.A., Alcamí, A. & Smith, G.L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551–560 (1995).
Alcamí, A. & Smith, G.L. A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153–167 (1992).
Lockyer, M.J., Davies, C.S., Suhrbier, A. & Sinden, R.E. Nucleotide sequence of the Plasmodium berghei circumsporozoite protein gene from the ANKA clone 2.34L. Nucleic Acid Res. 18, 376(1990).
Robson, K.J.H. et al. 84, 1–12 (1997).
jaffe, R.I., Lowell, C.H. & Gordon, D.M. Differences in susceptibility among mouse strains to infection with Plasmodium berghei (ANKA clone) sporozoites and its relationship to protection by gamma-irradiated sporozoites. Am. J. Trop. Med. Hyg. 42, 309–313 (1990).
Seguin, M.C. et al. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J. Exp. Med. 180, 353–358 (1994).
Renggli, J. et al. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol. 19, 145–148 (1997).
Weiss, W.R. et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J. Exp. Med. 171, 763–773 (1990).
Li, S. et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 90, 5214–5218 (1993).
Moss, B. et al. Host range restricted, non-replicating vaccinia vims vectors as vaccine candidates. Adv. Exp. Med. Biol. 397, 7–13 (1996).
Lanar, D.E. et al. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect. Immun. 64, 1666–1671 (1996).
Alcamí, A. & Smith, G.L., Vacinia, cowpox and camelpox viruses encode soulble interferon-v receptors with a novel broad species specificity. J. Virol. 69, 4633–4639 (1995).
Plebanski, M., Elson, C.J. & Billington Dependency on interleukin-1 of primary human in vitro T cell responses to soluble antigens. Eur. J. Immunol. 22, 2353–2358 (1992).
Though, D.F., Borrow, P. & Sprent, J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272, 1947–1950 (1996).
Khusmith, S. et al. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 252, 715–718 (1991).
Plebanski, M., Aidoo, M., Whittle, H.C. & Hill, A.V.S. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J. Immunol. 158, 2849–2855 (1997).
Hanke, T., Szawlowski, P. & Randall, R.E. Contruction of solid matrix-antibody-antigen complexes containing SIV p27 using tag-specific monoclonal antibody and tag-linked antigen. J. Gen. Virol. 73, 653–660 (1992).
Mackett, M., Smith, G.L. & Moss, B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49, 857–864 (1984).
Carroll, M.W. & Moss, B.E. E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. Biotechniques 19, 352–356 (1995).
Bodmer, H.C., Pemberton, R.M., Rothbard, J.B. & Askonas, B.A. Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein. Cell 52, 253–258(1988).
Gavin, M.A. et al. 151, 3971–3980 (1993).
Davis, H.L. et al. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine 12, 1503–1509 (1994).
Rodrigues, M. et al. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153, 4636–4648 (1994).
Brunner, K.T., Mauel, J., Cerottini, J.C. & Chapuis, B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14, 181–196 (1968).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schneider, J., Gilbert, S., Blanchard, T. et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4, 397–402 (1998). https://doi.org/10.1038/nm0498-397
Issue Date:
DOI: https://doi.org/10.1038/nm0498-397
This article is cited by
-
Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer
Cancer Cell International (2022)
-
ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge
npj Vaccines (2021)
-
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
Scientific Reports (2018)
-
Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii
BMC Infectious Diseases (2014)
-
Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1
Scientific Reports (2013)